Recent events, from COVID-19 to the war in Ukraine, have played havoc with supply chains around the world, resulting in major challenges to all kinds of companies, including those regulated by the Food and Drug Administration (FDA). On Oct. 6, 2022, the Food and Drug Law Institute (FDLI) will present “Supply Chain Mayhem: Industry Impacts and What Can Be Done,” a webinar moderated by Partner Winston S. Kirton.
The program will address impacts of major supply chain disruptions on FDA-regulated companies; strategies companies have taken or can take to mitigate their risk; findings from a review of supply chains undertaken by the FDA in 2021; and efforts by the federal government to stimulate domestic manufacturing of FDA-regulated components to avoid major impacts of supply chain disruptions in the future.
Panel participants include Christina Anderson Mooney, senior legal director of Medtronic; Amy Norris, executive counsel of Clif Bar & Company and member of the FDLI board of directors; and Howard R. Sklamberg, partner in Life Sciences & Healthcare Regulatory at Arnold & Porter LLP.
More information and to register.